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The secreted class 3 semaphorins, which include SEMA3F,a tumor-suppressor gene in lung cancer, were initially
identified as molecules involved in the repulsion of develop-
ing nerve growth cones. These molecules are part of a larger
family that includes transmembrane and membrane-associ-
ated proteins, some of which are expressed widely and
implicated in other functions such as development and im-
mune response.1 SEMA3B and SEMA3F are both encoded in
3p21.3,2–4 a region of frequent loss of heterozygosity in lung
cancer,5 which initially suggested that one or both of these
genes might have tumor-suppressor activity. Since this hy-
pothesis in 1996, several semaphorins have been implicated
in cancer.6–9 In this review, we focus on the function and
signaling of semaphorins involved in lung cancer.
SEMAPHORIN SIGNALING
The neuropilins (NRP) NRP1 and NRP2 are high-
affinity receptors for the class 3 semaphorins. However, in the
absence of plexin co-receptors, they are insufficient to prop-
agate a signal. Intracellular semaphorin signaling (Figure 1)
involves small-GTPases, collapsin response-mediated pro-
tein, pERK1/2, and integrins, which result in the reorganiza-
tion of tubulin and actin leading to modification of the
cytoskeleton and changes in cell adhesion and migration.10–12
Importantly, both NRP1 and NRP2 were also identified as
vascular endothelial growth factor (VEGF)165 co-receptors
and are required for vasculature development. Several reports
have indicated that class 3 semaphorins and VEGF165 com-
pete for NRP binding.6–9 Although semaphorin activity is
likely greater than just a VEGF antagonist, at least part of the
antitumor activity appears to stem from this function.
SEMAPHORIN ANTITUMOR ACTIVITY IN LUNG
CANCER
Initial expression studies demonstrated that levels of
SEMA3F mRNA were reduced in a majority of lung cancer
cell lines. In patient samples, protein levels of SEMA3F were
often reduced and its subcellular localization was shifted
from the plasma membrane to the cytoplasm.13 In non–small-
cell lung cancer, low SEMA3F levels were significantly
correlated with advanced stage disease. In addition, the pres-
ence of an exclusive cytoplasmic localization was signifi-
cantly correlated with high levels of VEGF165, increased
tumor grade, and aggressive disease.
In preneoplastic lesions, loss of SEMA3F protein staining
was frequently observed.14 Similarly, VEGF165 immunostaining
increased from low- to high-grade dysplasia and NRP levels
increased between dysplastic and microinvasive lesions. Thus,
deregulation of the VEGF165/SEMA3F/NRP pathway is a fre-
quent and early event in lung cancer pathogenesis. Subsequent in
vivo studies using immunodeficient mice or rats have confirmed
the capacity of SEMA3F to reduce or inhibit tumor develop-
ment.15–18 In these model systems, SEMA3F effects were both
antiangiogenic16,17 and antimetastatic.16 In the report of Kusy et
al.18 using a lung cancer orthotopic model, the antitumor effects
of SEMA3F were dramatic, with additional potential mecha-
nisms involving reduced adhesion to extracellular matrix sub-
strates and impaired signaling through the ERK pathway.
SEMA3B also has potent antitumor activity, as dem-
onstrated in nude mice where an ovarian adenocarcinoma cell
line transfected with SEMA3B showed reduced tumorigenic-
ity and cell proliferation.19 These in vivo results were con-
firmed in cell culture by SEMA3B transfection into the
non–small-cell lung cancer cell line, H1299, which resulted
in a greater than 90% reduction of colony formation.20 Fur-
thermore, in this cell line, SEMA3B overexpression induced
apoptosis, whereas VEGF165 led to cell proliferation.21
In summary, both SEMA3F and SEMA3B exhibit tu-
mor-suppressor activity in lung cancer and other tumor types.
Also of interest is the reported correlation between low levels
of collapsin response mediator protein 1 and increasing tumor
grade, invasion, and metastasis.22 Together with deregulation
of VEGF165 and NRP receptors, it is apparent that the overall
pathway(s) is affected in many, if not most, lung cancers.
Potential therapeutic approaches include up-regulation of
SEMA3F and SEMA3B expression by agents that target
chromatin reorganization and DNA methylation.6
The semaphorin molecule itself may prove useful as a
therapeutic agent.23 In addition, we suggest that a combined
approach involving VEGF inhibition and up-regulation of
SEMA3F/SEMA3B might be even more effective.
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FIGURE 1. Class 3 semaphorin signaling. Bind-
ing of class 3 semaphorins to neuropilin and
plexin leads to cytoskeleton reorganization, col-
lapse, cell repulsion, and changes in cell adhe-
sion. By competing with VEGF165 for binding to
neuropilin, they inhibit angiogenesis.
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